ChemGenex Pharmaceuticals
ChemGenex Pharmaceuticals Ltd, an integrated biopharmaceutical development company, engages in the discovery and the development of
About ChemGenex Pharmaceuticals
The story of Australian biopharmaceutical company ChemGenex is a classic tale of focusing on a core mission. Founded in 1999, the company, led by CEO and Managing Director Dr. Greg Collier, dedicated itself to developing treatments for cancer. The company's main focus became its lead product candidate, Omapro (omacetaxine), a treatment for patients with chronic myeloid leukemia. ChemGenex initially had a broader scope, also looking into metabolic diseases like diabetes and obesity. However, in 2007, the company made a strategic decision to restructure, demerging its metabolic disease assets to concentrate its resources entirely on its late-stage oncology portfolio. This sharpened focus allowed the company to advance its key cancer treatments through the demanding clinical trial process. The pivotal moment in the ChemGenex playbook arrived in March 2011. After navigating the ups and downs of drug development, including a setback from the US FDA, the company received a takeover offer from the US-based biopharmaceutical firm, Cephalon. Cephalon, which already held a significant stake in the company, offered to acquire the remainder of ChemGenex for approximately $163 million, a deal valued at about $231 million in total. The board of ChemGenex unanimously supported the offer, which represented a major premium on its share price. The acquisition was completed, and ChemGenex was delisted in July 2011, marking the end of its journey as an independent entity.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Mar 2011 | $225M | $225M | Cephalon | — |
| SERIES A✓Equity / VC | Mar 2007 | $21M | $84M | Alta Partners · GBS Venture Partners | — |
Growth signals
Latest recorded traffic for ChemGenex Pharmaceuticals is 0 monthly website visits, down 100% over the last three months. ChemGenex Pharmaceuticals's team grew 20% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
ChemGenex Pharmaceuticals in the Geelong ecosystem
The ChemGenex Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Alta Partners
GBS Venture Partners
Other known investors1 additional known investor
Cephalon
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ChemGenex Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ChemGenex Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








